Last reviewed · How we verify
IMV101 treatment — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
IMV101 treatment (IMV101 treatment) — Suzhou Immunofoco Biotechnology Co., Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| IMV101 treatment TARGET | IMV101 treatment | Suzhou Immunofoco Biotechnology Co., Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- IMV101 treatment CI watch — RSS
- IMV101 treatment CI watch — Atom
- IMV101 treatment CI watch — JSON
- IMV101 treatment alone — RSS
Cite this brief
Drug Landscape (2026). IMV101 treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/imv101-treatment. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing